Harvard Apparatus Regenerative Technology, INC Form 4 insider transactions

Junli He, CEO and a Director of Harvard Apparatus Regenerative Technology, Inc., reported multiple transactions in common stock on July 21, 2026.

Harvard Apparatus Regenerative Technology's CEO, He Junli, increased their stake by purchasing 3,000 shares of common stock.

Harvard Apparatus Regenerative Technology CEO, He Junli, purchased 300 shares of common stock at $1.98 per share.

Harvard Apparatus Regenerative Technology CEO He Junli acquired 11,225 shares of common stock at a weighted average price of $1.85.

Harvard Apparatus Regenerative Technology CEO, He Junli, purchased 4,050 shares of common stock at a weighted average price of $1.72, increasing beneficial ownership to 266,050 shares.

Harvard Apparatus Regenerative Technology, Inc. director Zhang Mao was granted 33,817 stock options with a $1.6 exercise price, comprising an annual equity grant and options in lieu of cash compensation, vesting over various future dates.

James E. Shmerling, a non-employee director of Harvard Apparatus Regenerative Technology, Inc., was granted 33,817 stock options with an exercise price of $1.60 per share as part of his compensation.

Herman Sanchez, a non-employee director at Harvard Apparatus Regenerative Technology, Inc., acquired 33,817 stock options with an exercise price of $1.60 per share, through a combination of annual equity grant and options in lieu of cash compensation.

Ronald J. Packard, a director at Harvard Apparatus Regenerative Technology, Inc. (HRGN), was granted a total of 33,817 stock options with an exercise price of $1.6 per share, as part of his annual equity compensation and in lieu of cash compensation.

Director Li Ting of Harvard Apparatus Regenerative Technology, Inc. was granted 33,817 stock options with a $1.6 exercise price, comprising an annual equity grant and an award in lieu of cash compensation.

Harvard Apparatus Regenerative Technology, Inc. director David Green was granted 33,817 stock options with an exercise price of $1.60, comprising annual equity and compensation-in-lieu grants.

Harvard Apparatus Regenerative Technology, Inc. Director Chen Jing was granted 33,817 stock options with an exercise price of $1.60 per share on June 27, 2025, as part of annual equity compensation and in lieu of cash.

HREGEN CEO Junli He acquired 2,299 shares of common stock at a weighted average price of $2.87 per share.

Director Zhang Mao acquired stock options in Harvard Apparatus Regenerative Technology, Inc. on September 3, 2024, as part of an annual equity grant.

CEO of Harvard Apparatus Regenerative Technology, He Junli, reports the acquisition of common stock through a series of transactions.

DST Capital LLC reports the transfer of warrants in Harvard Apparatus Regenerative Technology, Inc. to unaffiliated persons.

Ronald J. Packard, a director of Harvard Apparatus Regenerative Technology, Inc., acquired stock options through an equity grant and in lieu of cash compensation.

Director Ting Li acquired stock options in Harvard Apparatus Regenerative Technology, Inc. on June 27, 2024.

James E. Shmerling, a director of Harvard Apparatus Regenerative Technology, Inc., acquired stock options as part of his compensation.

Director Herman Sanchez receives stock options as part of annual equity grant and in lieu of cash compensation from Harvard Apparatus Regenerative Technology, Inc.

David Green, a director at Harvard Apparatus Regenerative Technology, Inc. (HRGN), was granted stock options on June 27, 2024, as part of his annual equity grant and in lieu of cash compensation.

Director Chen Jing receives stock options as part of annual equity grant and in lieu of cash compensation.

He Junli, CEO of Harvard Apparatus Regenerative Technology, reports the acquisition of 1,600 shares of common stock.